Industry & Policy News

[Salk Institute] Salk Institute Assistant Professors Christina Towers and Deepshika Ramanan were named V Scholars by the V Foundation for Cancer Research. They will each receive $600,000 over three years to fund their unique cancer research goals.

[Brain Tumour Research] Launched to mark the end of Childhood Cancer Awareness Month, Brain Tumour Research, Leukaemia UK, and Sarcoma UK ave formed a pioneering collaboration that is dedicated to funding groundbreaking research into the prevention, treatment and cure of the most common childhood cancers.

[Smart Immune] Smart Immune announced that the first patients have been dosed in its ReSET-02 Phase I/II trial for adult acute leukemia and myelodysplasia syndrome patients. Two patients have now received the first dose level of SMART101, an allogeneic cell therapy produced from donor-mobilized peripheral blood stem cells and differentiated into T-cell progenitors through Smart Immune’s ProTcell therapy platform.

[Profound Medical Corp. (Globe Newswire)] Profound Medical Corp. announced that it has received 510(k) clearance from the US FDA for the Company’s Thermal Boost module for use in conjunction with TULSA-PRO®.

[University of South Carolina] The Keck School of Medicine of University of South Carolina (USC) has received funding from the National Institutes of Health as part of a five-year, $50.3 million “multi-omics” study of human health and disease involving six sites.

[Fierce Biotech] AbbVie has decided it can do without Caribou Biosciences. The Big Pharma is terminating its off-the-shelf CAR-T pact with the biotech, depriving Caribou of the chance to pocket up to $350 million in milestones per program.